etoposide has been researched along with rhamnetin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP | 1 |
2 other study(ies) available for etoposide and rhamnetin
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2016 |